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Immobilization of arrestin-3 on different
biosensor platforms for evaluating GPCR binding†
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Martin K. Ostermaier, e Elena Lesca*cd and Cornelia G. Palivan *a
G protein-coupled receptors (GPCRs) are a large and ubiquitous family of membrane receptors of great
pharmacological interest. Cell-based assays are the primary tool for assessing GPCR interactions and
activation but their design and intrinsic complexity limit their application. Biosensor-based assays that
directly and specifically report GPCR-protein binding (e.g. arrestin or G protein) could provide a good
alternative. We present an approach based on the stable immobilization of different arrestin-3 proteins
(wild type, and two mutants, mutant X (arrestin-3 I386A) and mutant Y (arrestin-3 R393E)) via histidine
tags on NTA(Ni2+)-coated sensors in a defined orientation. Using biolayer interferometry (BLI), surface
plasmon resonance (SPR), and quartz crystal microbalance with dissipation (QCM-D), we were able to
follow the interaction between the different arrestin-3 proteins and a representative GPCR, jumping
spider rhodopsin-1 (JSR1), in a label-free manner in real-time. The interactions were quantified as
binding affinity, association and dissociation rate constants. The combination of surface-based
biosensing methods indicated that JSR1 showed the strongest binding to arrestin mutant Y. Taken
together, this work introduces direct label-free, biosensor-based screening approaches that can be
easily adapted for testing interactions of proteins and other compounds with different GPCRs.
1 Introduction
G protein-coupled receptors (GPCRs) are the largest family of
membrane proteins that sense the extracellular environment in
animals and transduce the information into the cell in order to
coordinate a broad range of physiological processes including
vision, olfaction, neural signal transmission, and pain.1,2 The
stimuli that activate GPCRs are physically and chemically diverse,
for example neurotransmitters, hormones, odorants, ions, and
light.3 All GPCRs have a similar structure: an extracellular
N-terminus, seven a-helices, and an intracellular C-terminus. The
extracellular domain contains a pocket for the ligand, while the
intracellular region interacts with binding proteins such as
G-protein or arrestin. Upon activation, conformational changes
occur from the ligand-binding pocket to the cytosolic region,
starting G protein-mediated signaling cascades. In order to
control the number of activated receptors, GPCR kinases (GRKs)
phosphorylate the cytoplasmic region (e.g. the C-tail) of the
receptor triggering the binding of arrestin, which prevents G
protein binding to the receptor.
Most vertebrates express four arrestin subtypes. Rods and
cones visual arrestins (respectively arrestin-1 and arrestin-4) are
selectively expressed in the retina, while non-visual b-arrestins
1 and 2 (also known as arrestin-2 and arrestin-3, respectively)
are ubiquitously expressed and regulate many different
GPCRs.4 Arrestins have no enzymatic activity but can assemble
in multi-protein signaling complexes or deactivate GPCRs and
other receptor types.5 Arrestin interacts with GPCR predomi-
nantly at two sites: the arrestin finger-loop penetrates the
cytosolic side of the receptor, while elements of the N-
terminal domain engage the phosphorylated C-tail of the
receptor.6 These interactions prevent GPCR activation through
G-protein and simultaneously promote receptor internalization,
directing GPCRs to lysosomes for degradation or recycling them
back to the plasma membrane where they are reused in signaling.
Therefore, targeting specific arrestin-GPCR interactions has thera-
peutic potential. Different strategies are being considered in the
context of developing arrestin-related therapeutics:5 (i) proteins that
compete with GPCRs for binding arrestin, (ii) peptides or small
molecules that disrupt GPCR-arrestin interactions, or (iii) the use of
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arrestin mutants to control excessive signaling by GPCRs. However,
in order to develop therapeutics targeting GPCR–arrestin inter-
actions, the precise identification of interaction sites as well as
knowledge of the binding affinity between arrestin and the
respective binding partners are necessary.
Cell-based assays are mainly used to investigate the GPCR-
arrestin interactions because GPCRs need to be stabilized by
the phospholipid bilayer and phosphorylated prior to binding
arrestin.7,8 Approaches such as bioluminescence and fluorescence
resonance energy transfer (BRET and FRET, respectively) are used
to study different GPCR functions in intact cells either statically or
in real-time.9–11 However, protein labeling might interfere with
GPCR–arrestin interactions and thus, might influence experi-
mental outcomes. In addition, the activity of the receptor on the
cell surface has been monitored by a reporter assay, which
indirectly measures changes in the concentration of down-
stream signaling molecules such as second messengers.12,13
Although using reporters or indirect measurements in cells
provide qualitative evidence of GPCR–arrestin interactions, it
is very difficult to quantify the kinetic parameters of such
interactions due to the interference from other cellular compo-
nents of GPCR signaling and exogenous protein overexpression.
Alternatively, label-free biosensor technologies lend them-
selves to quantifying GPCR interactions. Commonly used label-
free biosensor technologies are biolayer interferometry (BLI),
surface plasmon resonance (SPR) and quartz crystal microbalance
with dissipation monitoring (QCM-D).14 In order to investigate
GPCR–protein interactions, several methods for the immobilization
of GPCR on biosensors have been proposed including antibody-
mediated attachment, avidin–biotin based capture procedures, or
the reconstitution of GPCR within physiologically relevant environ-
ments (e.g. liposomes, and nanodiscs).15–18 By these means, the
interactions of G protein with immobilized receptors have been
monitored. For example, immobilized bovine rhodopsin (BRho)
enabled exploring G protein activation and receptor deactivation
using SPR.19 In order to study the association of b-arrestin-1 with
the C–C chemokine receptor 5 (CCR5), different immobilization
strategies were pursued. Either an N-terminal cysteine residue of
CCR5-derived peptides was coupled to the thiol groups of a CM5
biosensor or peptides corresponding to the CCR5 IL-3 cytoplas-
mic loop were synthesized with an N-terminal biotin moiety and
immobilized to a streptavidin sensor surface.20 However, the
immobilization of native GPCR receptors on the sensor surface
might have certain disadvantages, such as random orientation,
inaccessibility of the binding site or conformational changes
interfering with receptor function. Since specific conformational
changes are a prerequisite for arrestin binding and GPCRs
require lipids or detergent molecules to be stabilized, it might
be better to immobilize binding protein and allow the receptor to
be free in order to trigger protein–protein interactions of interest.
Besides, immobilization of the GPCRs on the biosensor requires
extensive optimization procedures and thus, large amounts of
GPCR which in itself is a big challenge due to difficulties in
purifying GPCRs without altering their functional characteristics.
Here we present a straightforward platform to study the interaction
between GPCRs and arrestin-3 requiring minimal amounts of
recombinantly expressed, functional proteins. This strategy is based
on the surface immobilization of arrestin-3, a GPCR partner that
appears to also interact with non-phosphorylated receptors.21,22 We
combine label-free biosensor technologies, specifically BLI, SPR
and QCM-D in order to provide an overview of the changes in
GPCR/arrestin-3 interactions when arrestin-3 is immobilized on
different surfaces.
For our assays we chose to immobilize non-visual arrestin-3
(Arr3) because it is the least selective member of the arrestin
family and binds to many different GPCRs.23 In addition to
wild-type arrestin-3 (Arr3-WT), two arrestin-3 mutants, I386A (Arr3-X)
and R393E (Arr3-Y) were studied. According to cell-based assays,
these two variants have been suggested to show a higher sensitivity
towards activated GPCRs than Arr3-WT.24,25 Each of the mutations
affects one of two stabilizing binding sites of arrestin-3 (Fig. 1):
R393E results in a change of the arrestin polar core and I386A
impinges on three-element interaction. Both are predicted to
result in a ‘‘pre-activated’’ form of arrestin leading to an
increased receptor coupling affinity compared to Arr3-WT.
As a model GPCR we selected Jumping Spider Rhodopsin-1
(JSR1), a light-sensitive bistable class A GPCR, which has
recently been shown to be highly thermostable in its wild-type form
in vitro26 and is an interesting target for the development of
optogenetic tools.26,27 In fact, as other rhodopsins, JSR1 is easily
activated by illumination without the addition of ligands. Moreover,
invertebrate rhodopsins are known to be able to bind arrestin in a
phosphorylation-independent way upon illumination.28 Finally, the
high resolution crystal structure of JSR1 (PDB ID 6I9K)26 shows
Fig. 1 Schematic representation of possible interactions between DDM-
stabilized JSR1 and immobilized Arr3. Arrestin-3 (PDB ID: 3p2d4) is immobilized
via a histidine-tag to multivalent chelator headgroups on a supported lipid
bilayer (SLB) or monolayer (SLM). Two distinct interaction interfaces with JSR1
(PDB ID: 6i9k26) are indicated by dotted circles: (1) JSR1 C-tail interactions with
the N domain of Arr3 and (2) the hydrophobic inter-domain interactions. The
replacement of the positively charged (blue) arginine to the negatively charged
(red) glutamic acid (R393E mutation in the polar core, which is indicated by
shaded area) interferes with charge interactions, which normally keep the
binding inaccessible for the C-terminus of the receptor, thus likely inducing a
pre-activated state of Arr3. The I386A mutation in Arr3-X is located in the region
involved in three-element-interactions (TE-interaction, shaded area) and might
help the N-terminus of Arr3 to disengage from an intramolecular binding, thus
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similarities between JSR1 and other non-light sensitive class A
GPCRs26 suggesting JSR1 as a valid model for in vitro binding
studies.26,27 At the same time, we establish here a platform,
which allows an in-depth biophysical characterization of
arrestin binding of any GPCR with pharmaceutical relevance.
We evaluated different surface-based methods, specifically
BLI, SPR and QCM-D, which allow the quantitative evaluation
of the interaction of WT and mutant arrestin-3 with JSR1.
Specifically, Arr3 was immobilized on commercially available
Ni2+–NTA-containing, portable BLI tips which have no lipid layer.
Then, using vesicle fusion, we formed a Ni2+–NTA functional
supported lipid bilayer (SLB) on silicon oxide (QCM-D sensor)
and a lipid monolayer (SLM) on HPA chips (SPR sensor),
respectively. The advantage of SLBs is that they enable lateral
mobility and thus provide a biologically relevant environment.
SLMs and functionalized BLI tips on the other hand, represent
platforms with restricted translational fluidity and thus higher
stability, which are more resistant to the detergents necessary to
stabilize the GPCRs. We were able to evaluate the binding of
JSR1 to Arr3 and its mutants and calculate the equilibrium
dissociation constants (KDs), and association and dissociation
rate constants (ka and kd, respectively) for these interactions.
Such information will provide the basis for finding stronger
binders among candidates in drug design approaches.
2 Experimental methods
2.1 Expression and purification of JSR1
Wild-type JSR1 with a C-terminal 1D4 epitope tag was expressed
and purified as described in Ehrenberg et al.27 Briefly, a suspen-
sion culture of HEK293S GnTI-cell line stably expressing JSR1 was
cultivated in FreeStyle 293 expression medium to 2  106 cells per
mL and then harvested. Frozen cells were mechanically homo-
genized in 50 mM HEPES, 140 mM NaCl, and 3 mM MgCl2 with
protease inhibitors (Roche complete EDTA-free Protease Inhibitor
Cocktail; Sigma-Aldrich, Buchs, Switzerland) and incubated over-
night with 30 mM 9-cis retinal (98% grade, Sigma-Aldrich) over-
night at 4 1C in the dark for reconstitution with the chromophore.
JSR1 membranes were solubilized in the same buffer supplemen-
ted with 1% n-dodecyl-b-D-malto-pyranoside (DDM) (Anagrade;
Anatrace, Maumee, OH) for 2 h at 4 1C. Solubilized JSR1 was
separated from the membrane fraction by ultracentrifugation at
100 000g for 1 h at 4 1C. Subsequently, JSR1 was purified from the
supernatant by 1D4-antibody affinity chromatography as described
in Varma et al.26 JSR1 purity was assessed by SDS-PAGE and UV-vis
spectroscopy. Purified JSR1 was stored in 50 mM HEPES, 150 mM
NaCl, 1 mM MgCl2 with 0.01% DDM at pH 6.5.
2.2 Cloning and expression of arrestin-3 proteins
Arr3-WT with an N-terminal hexahistidine followed by a TEV
protease cleavage site (ENLYFQGGS) was cloned into the
pET-15b vector (Novagen).29 Arr3-X (I386A) and Arr3-Y (R393E)
(identified by InterAx Biotech) mutant constructs were produced
by site-specific PCR mutagenesis using the pET-15b Arr3-WT plas-
mid as template.30,31 For arrestin-3 expression, chemically competent
NiCo21(DE3) E. coli cells (New England Biolabs) were transformed
with the corresponding plasmid. Expression was induced in high-
density cultures strictly following the described procedure.
2.3 Arrestin-3 protein purification
Histidine tagged Arr3-WT and Arr3 mutants were purified as
described elsewhere29 with minor modifications. Briefly, cells
were resuspended in solubilization buffer (50 mM Bis–Tris
propane pH 7.0, 500 mM NaCl and 10% (v/v) glycerol) and
lysed by 3 cycles of sonication. The clarified lysate was supple-
mented with 30 mM imidazole and purified over a 5 mL
Ni–NTA FF crude column (GE Healthcare). The pooled protein
fractions were dialyzed over night against dialysis buffer A
(20 mM Bis–Tris propane pH 7.0, 120 mM NaCl, 10% (v/v)
glycerol and 14.3 mM 2-mercaptoethanol) without adding TEV
protease to preserve the N-terminal His-tag for immobilization.
The dialyzed protein solution was diluted to a final salt concen-
tration of 40 mM NaCl using dilution buffer (dialysis buffer
without NaCl) and subsequently applied to a 15 mL Q sepharose
column. After washing with Q sepharose buffer A (20 mM
Bis–Tris propane pH 7.0, 40 mM NaCl, 10% (v/v) glycerol and
14.3 mM 2-mercaptoethanol) until a stable baseline was
reached, the protein was eluted in Q sepharose buffer B
(20 mM Bis–Tris propane pH 7.0, 200 mM NaCl, 10% (v/v)
glycerol and 14.3 mM 2-mercaptoethanol). Finally, Arr3 proteins
were purified over a Superdex 200 Increase 10/300 GL column
(GE Healthcare) equilibrated in SEC buffer (20 mM Bis–Tris
propane pH 7.0, 300 mM NaCl, 10% (v/v) glycerol and 14.3 mM
2-mercaptoethanol). Pooled protein fractions were concentrated
using a 30 kDa MWCO Millipore spin concentrator (Merck).
Aliquots of Arr3 proteins were shock frozen in liquid nitrogen
and stored at 80 1C.
2.4 POPC:DGS-NTA(Ni2+) vesicle preparation
1-Palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC) and 1,2-
dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic
acid)succinyl] (nickel salt) (DGS-NTA(Ni2+)) were obtained in
chloroform from Avanti Polar Lipids (Alabaster, AL). Lipids were
mixed at the desired molar ratio in a round-bottom glass flask.
Dried lipid films were formed by evaporating the chloroform upon
exposure to a gentle stream of nitrogen gas. The dried lipid films
were placed in a vacuum desiccator overnight in order to remove
residual chloroform. Subsequently, they were hydrated in 20 mM
HEPES, pH 7.4 containing 150 mM NaCl, and vortexed for one
minute. The resulting vesicle suspension was sequentially
extruded through a track-etched polycarbonate membrane with
100 nm and then 50 nm diameter pores for a minimum of 21
times using a Mini Extruder apparatus (Avanti Polar Lipids).
2.5 Dynamic light scattering (DLS)
The size distribution of lipid vesicles was characterized using
a Zetasizer nano ZSP (Malvern Instruments, Malvern, UK).
The scattering was recorded at a fixed and backscattering angle
of 1731. The average effective hydrodynamic diameter of
the vesicles and the sample polydispersity are recorded. All
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2.6 Quartz crystal microbalance with dissipation (QCM-D)
A Q-Sense E1 instrument (Biolin Scientific, Gothenburg, Sweden)
was used in order to monitor lipid and protein adsorption
processes through changes in resonance frequency (DF) and
dissipation (DD) of a silicon oxide-coated quartz crystal (model
no. QSX303) as a function of time. The QCM-D measurement
data were collected at the 3rd, 5th, 7th, 9th, and 11th odd
overtones. The QCM-D data reported were all obtained at the
5th overtone and normalized accordingly (DFn = 5/5). Immedi-
ately before the experiment, the QCM-D sensor substrates were
sequentially rinsed with 1% SDS, water, and ethanol followed by
drying with nitrogen gas. The substrates were then subjected to
oxygen plasma treatment (Harrick Plasma, Ithaca, NY) at the
maximum radiofrequency (RF) power. All QCM-D measurements
were conducted under continuous flow conditions controlled by
a Reglo Digital peristaltic pump (Ismatec, Glattbrugg, Switzer-
land), with the flow rate set to 100 mL min1 for bilayer formation
and washing processes and 50 mL min1 for protein addition and
adsorption. The temperature of the flow cell was fixed at 24.0 
0.5 1C. The molecular ratio of adsorbed proteins was estimated by
applying the Sauerbrey model to convert frequency shifts into
mass density values as follows:
Dm = CDFn
where Dm is the adsorbate mass, C is the proportionality
constant (17.7 ng cm2), DF is the frequency shift, and n is
the odd overtone number of the resonance frequency.32
2.7 Surface plasmon resonance (SPR)
SPR binding assays were performed using a BiacoreT200 (GE
Healthcare) and Biacore T200 Control software (version 2.0.1)
at 25 1C with four parallel flow cells. A supported lipid mono-
layer (SLM) was established on the HPA chip (GE Healthcare), a
flat hydrophobic surface consisting of long-chain alkanethiol
molecules directly attached to the gold film, by fusion of
POPC : DGS-NTA(Ni2+) (95 : 5) vesicles to the hydrophobic
surface of this sensor chip in buffer (20 mM HEPES, pH 7.4
containing 150 mM NaCl). On the resulting SLM layer, His-tagged
wild-type arrestin3 (Arr3) and its mutants X (Arr3-X) and Y (Arr3-Y)
were immobilized. JSR1 was then injected into all for flow
channels to measure its binding to arrestins (immobilized in
the flow channels 2, 3 and 4, respectively). The first flow channel
was used as a reference to compensate for the SPR signal
change caused by unbound JSR1 during injection. The binding
data were analyzed using Biacore T200 Evaluation software
(version 3.0). The stoichiometric ratio of DDM stabilized JSR1
binding to Arr3 was calculated as follows;
(Rmax/MW of JSR1 in DDM)/(Rimm/MW of Arr3)
where Rmax is the maximal binding response for JSR1 (i.e. when all
arrestins on the surface are occupied by JSR1) and is proportional
to the molecular weight of JSR1 in DDM (116 kDa) that could be
bound per surface unit, and Rimm is the response for the Arr3
immobilization, and is proportional to the molecular weight of Arr3
(48 kDa) bound per surface unit during the immobilization.33
2.8 Bio-layer interferometry (BLI)
Label-free bio-layer interferometry experiments were performed
on the BLItz instrument (ForteBio, Inc., USA) with BLItz Prot
analysis software. The his-tagged arrestin3 samples (4 mL of
1 mM each) were immobilized on the commercially available
ForteBio Ni–NTA biosensors coated with a biocompatible
matrix made of QIAGEN’s agarose resin that is uniform and
non-denaturing with minimal nonspecific binding. The pro-
vided ‘Dip and Read’ assay was used to monitor specific protein
binding. Binding of the specific protein to the surface leads to
the increase in the optical thickness of the bio-layer, resulting
in the shift of the wavelength (in nm). All experiments were
performed in 20 mM HEPES, pH 7.4 with 150 mM NaCl.
3 Results and discussion
3.1 Supported lipid monolayer and bilayer formation on
different sensors
In order to generate platforms with immobilized arrestin, we
first created SLM and SLB platforms on SPR and QCM-D
sensors, respectively, exposing Ni–NTA for histidine binding.
SLM and SLB surfaces were prepared by vesicle adsorption,
fusion, rupture, spreading, and lipid reassembly on the solid
support.34,35 For SPR measurements, we used a hydrophobic
HPA sensor surface for SLM formation whereas a hydrophilic
silicon oxide QCM-D sensor served as an SLB support. Due to
the different intrinsic properties of SLM and SLB, i.e. their
fluidity and thickness, the interaction of arrestin with JSR1
stabilized in detergent micelles might vary depending on the
platform. Similar to biological membranes, the SLB platform
enables lateral mobility, which can be a crucial parameter for
proper protein conformation. SLM on the other hand, is a more
stable membrane that more likely resists GPCR stabilizing
detergents. For SLM and SLB formation, the lipid vesicles were
composed of a mixture of 95 mol% 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-choline (POPC) and 5 mol% Ni–NTA functionalized lipids
(1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic
acid)succinyl] (nickel salt), DGS-NTA(Ni2+)), where the latter enables
the immobilization of histidine-tagged proteins.36 The obtained
vesicles were 77.23  3.6 nm in diameter and had a polydis-
persity index (PDI) of 0.06  0.016 as determined by dynamic
light scattering.
The SLM formation process was monitored by SPR (Fig. 2A
and B). Real-time changes in the SPR angle were recorded as
resonance units (RU), being proportional to the amount of the
material deposited on the sensor.35 An optimal SLM coverage of
the sensor was obtained when the lipid vesicles were injected
at a low flow rate (2 mL min1) immediately after a cleansing
pulse of 40 mM octyl glucoside (n-octyl b-D-glucopyranoside)
(2 mL min1). This resulted in an SPR response within the range
of 1500–2500 RU as is expected for a uniform lipid monolayer
on the sensor.37 SLB formation on silicon oxide sensors was
followed by QCM-D (Fig. 2C and D). Changes in mass (Dm) were
derived from frequency (DF) shifts, which were simultaneously
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properties of layers formed on sensors were represented as changes
in dissipation (DD) (Fig. S1B, ESI†). Because the frequency shift is
negatively proportional to the adsorbed mass, a Dm of approximately
450 ng cm2 was calculated, indicating the formation of a uniform
lipid bilayer. For all SLB platforms, the final QCM-D measurements
corresponded to DF and DD values of 24.04  2.17 Hz and o1 
106, respectively, which agree well with literature values for SLB
systems.34,39,40 In contrast to QCM-D and SPR sensors, BLI sensors
are provided with polymer coatings that include Ni-NTA for histidine
binding and thus, were not further modified.
3.2 Immobilization of Arr3 on different biosensors
The capture of Arr3, Arr3-X, and Arr3-Y on the sensor surfaces
was achieved through interaction between the 6-histidine tag
(His6) of the arrestin and nickel charged tris-nitrilotriacetic
(NTA(Ni2+)) exposed on the respective biosensors. Because sur-
face immobilization occurs via the N-terminal His6 tag, the finger
loop structure in arrestin presumably is not perturbed and thus,
is available for the interaction with JSR1 (Fig. 1).
For BLI measurements, 1 mM of Arr3 was added to the
NTA(Ni2+) functionalized sensors (Fig. 3A) and immobilization of
Arr3 changed the interference pattern of the reflected light, causing
a wavelength shift that was recorded as a function of time.
For the immobilization of Arr3 to SLM-coated SPR biosensors,
1 mM of Arr3 was injected to the platforms. Immobilization
experiments for Arr3 were repeated at least 3 times. In order to
control the amount of immobilized Arr3 on the SPR sensor, we
changed the amount of DGS-NTA(Ni2+) content (1, 5 and 20%) in
the vesicles used for SLM production. Representative sensorgrams
recorded upon addition of Arr3-WT are presented in Fig. 3B. The
binding response was related to the content of DGS-NTA(Ni2+) in
SLM (Table 1).
At the highest DGS-NTA(Ni2+) content, the change in SPR
response corresponded to 3692  1800 RU, from which, using
the relation 1300 RU = 1 ng mm2, a surface adsorption of
284  138 ng cm2 Arr3-WT was calculated.41 Increasing DGS-
NTA(Ni2+) lipids within the SLM layer up to 20% results in an
estimated distance between NTA-lipids of less than 3 nm.
In this case, the arrestin immobilization capacity would be maximal
and limited only by the size of arrestin itself. In order to compare
binding profiles of wild type and mutant Arr3, we fixed the
concentration of DGS-NTA(Ni2+) in the vesicles to 5 mol% and
added 1 mM of the different arrestins (Fig. 3C). The results indicated
that Arr3-WT led to a final response of 306  52 RU whereas the
final responses from Arr3-X and Arr3-Y (about 1000 RU) were similar
but higher than the response obtained from Arr3-WT.
For QCM-D measurements, we limited the fraction of functional
DGS-NTA(Ni2+) to 10% maximum since higher amounts of
functionalized lipids might hinder the formation of SLBs on
silicon oxide. After SLB formation on QCM-D biosensors with
1–10% of DGS-NTA(Ni2+), the QCM-D readouts for mass signals
were re-equilibrated and set to zero to specifically focus on the
immobilization of Arr3-WT. 120 nM Arr3-WT were injected to
DGS-NTA(Ni2+) containing SLBs and the Dm as a function
Fig. 2 Supported lipid monolayer and bilayer formation by vesicle fusion. (A) Schematic illustration of SLM platform on an SPR sensor. (B) A
representative SPR response of SLM formation on HPA sensor (number of replicates, n = 3). Arrows indicate first, an injection of vesicles made of
POPC:DGS-NTA(Ni2+) (95 : 5), and then an injection of buffer (20 mM HEPES, 150 mM NaCl at pH 7.4). 2280 RU correspond to 175 ng cm2 of adsorbed
lipids. (C) Schematic representation of SLB platform on a QCM-D sensor. (D) Changes in mass were recorded as function of time upon formation of SLBs.
The numbers at the top denote the injection of (1) buffer (20 mM HEPES, 150 mM NaCl at pH 7.4) containing 5 mM MgCl2, (2) vesicles made of
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of time (Fig. 4A) were calculated from DF. Upon injection of
Arr3-WT, an increase in mass was observed.
The DF ranged from 6.03  0.17 Hz at 1 mol% DGS-
NTA(Ni2+) to 43.10  2.5 at 10 mol% DGS-NTA(Ni2+)
(Table 2). Increasing the amount of DGS-NTA(Ni2+) in the SLB
did not result in a significant change of dissipation energy over
time, suggesting that the conformation of bound Arr3-WT, which
is related to the viscoelastic properties, is unchanged for the
concentrations used. Additionally, since DD was around 1  106
for DGS-NTA(Ni2+) from 1% to 10%, Sauerbrey equation has been
applied to quantify the surface density of attached Arr3-WT.32
The mass of Arr3-WT varied from 106.73  3.003 ng cm2 at
1 mol% DGS-NTA(Ni2+) up to 762.78 44.43 ng cm2 at 10 mol%
DGS-NTA(Ni2+) (Table 2) indicating that higher amounts of
chelator lipids in SLBs led to higher amounts of immobilized
of Arr3-WT. In the absence of DGS-NTA(Ni2+), i.e. at 100% POPC,
both DF and DD did not change upon addition of Arr3-WT. This
confirms that the immobilization of Arr3-WT on the SLB platforms
occurs specifically through the interaction between histidine tag
and NTA(Ni2+). Initially, Arr3-WT in solution monovalently binds to
the chelator lipid. Due to the fluidity of bilayers, Arr3-WT will
encounter additional chelator lipids, resulting in polyvalently
bound, stable Arr3-WT/DGS-NTA(Ni2+) lipid complexes. Thus, in
addition to varying the DGS-NTA(Ni2+) fractions in SLBs, incubation
conditions of Arr3-WT (e.g. time or concentration) can also be
modified to tune the amount of bound proteins on SLBs.36
In order to further compare the immobilization profiles of
WT and mutant Arr3, we fixed the concentration of DGS-NTA(Ni2+)
in the vesicles to 5 mol % and added 120 nM of the different
arrestins (Fig. 4B). Under these conditions, WT and mutant Arr3
showed similar mass adsorption.
3.3 Probing the interaction between JSR1 and immobilized Arr3
To explore the interaction of immobilized arrestins with JSR1
by QCM-D, we first tested the binding activity of the platform
using the negatively charged polysaccharide heparin as a model
system since it has been shown that heparin competes with light-
activated phosphorylated rhodopsin for binding to arrestin.42
When heparin was injected to SLBs with immobilized Arr3-
WT, a DF was recorded and converted to the number of heparin
molecules bound by taking into account molecular weights of
Arr3-WT (48 kDa) and heparin (5 kDa) (Fig. 5A) The numbers
of Arr3-WT bound to SLBs and heparin bound to Arr3-WT
increased as a function of DGS-NTA(Ni2+) content. At 1 mol%
DGS-NTA(Ni2+), 13.34  0.37  1011 molecules of Arr3-WT per cm2
were bound whereas the number of bound heparin molecules was
Fig. 3 Immobilization of WT and mutant Arr3 on BLI and SPR biosensors. (A) Capture of different arrestins (1 mM) to BLI Ni2+–NTA tips. (B) Change of the
SPR response upon Arr3-WT (1 mM) addition to SLMs with different molar percentage of DGS-NTA(Ni2+). (C) Change of the SPR response upon Arr3-WT,
mutants Arr3-X and Arr3-Y binding to SLM with 5% of DGS-NTA(Ni2+). Curves representing one of three independent measurements are shown.
Table 1 Summary of SPR response (RU) and mass adsorption for Arr3 WT
immobilized to SLMs with different content of DGS-NTA(Ni2+). Each data
point represents average  standard deviation of three independent
measurements
DGS-NTA(Ni2+)
content (%) SPR response (RU) Adsorbed mass (ng cm2)
1 306  52 23.5  5.2
5 522  95 40.2  4
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13.53  2.56  1011 cm2, indicating that each heparin was bound
to one Arr3-WT molecule. Increasing the mol% of DGS-NTA(Ni2+)
changed the stoichiometry between heparin and Arr3 WT. At 10% of
DGS-NTA(Ni2+), each Arr3-WT bound approximately 2.3 heparin
molecules. However, this calculation might overestimate the stoi-
chiometry between Arr3-WT and heparin since in QCM-D bound
water in addition to mass of the protein cannot be subtracted.
To compare the immobilization of Arr3-WT with mutant
Arr3-X and Arr3-Y, SLB membranes with 5 mol % of DGS-NTA(Ni2+)
were prepared. Absolute changes upon binding of heparin with
Arr3 are presented in Fig. 5B. A similar Dm of heparin was
obtained for Arr3-X and Arr3-Y, and it was higher compared to
Arr3-WT. Specifically, the bound mass of heparin was 208.74 
17.72 ng cm2 on Arr3-X containing SLBs while it was 148.33 
09.3 ng cm2 on Arr3-WT containing SLBs. In the absence of
Arr3 there was no binding of heparin to SLB platforms.
Interaction of heparin with Arr3 was verified using BLI, and
an equilibrium dissociation constant of 400  103 nM (ka =
1.6  0.41  105 M1 s1 and kd = 0.064  0.002 s1) was
determined, indicative of a very stable binding (Fig. S2 and
Table S1, ESI†). The presented data on the interaction arrestin/
heparin are a functional indication of the activity of our recombi-
nant arrestin.42
We next characterized JSR1–arrestin-3 interactions in different
environments, either by mimicking a cell membrane (SLB plat-
form) or by providing more stability (SLM platform) which is
important for the further development of screening assays.
To test the interaction between immobilized Arr3 and JSR1, we
first activated JSR1 by illuminating it with a blue laser (495 nm)
for 1.5 minutes in all experiments.
In the case of BLI, tips derivatized with WT and mutant Arr3
were dipped into five different concentrations of JSR1 (0.125,
0.250, 0.500, 1, and 4.3 mM) stabilized in DDM micelles. The
Fig. 4 Immobilization of Arr3 proteins on SLB. (A) Changes in mass were
recorded upon sequential addition of Arr3-WT on SLBs made up from 0 to
10% DGS-NTA(Ni2+) lipids. Arrows denote the injection of 120 nM Arr3 and
the rinsing with buffer (20 mM HEPES, 150 mM NaCl at pH 7.4).
(B) Changes in mass were recorded upon addition of Arrestin-3 protein.
After the SLB formation, Arr3-WT (black squares), Arr3-X (red circles), and
Arr3-Y (blue triangles), were immobilized on SLB with 5% DGS-NTA(Ni2+).
Table 2 Summary of DF and Sauerbrey mass for Arr3-WT immobilization
to SLBs with different molar percentage of DGS-NTA(Ni2+). Each data point
represents average  standard deviation of two independent measurements
DGS-NTA(Ni2+) content (%) DF (Hz) Mass (ng cm2)
0 1.18  0.62 20.79  10.88
1 6.03  0.17 106.73  3.003
2.5 21.01  0.66 371.877  11.76
5 33.71  3.7 596.69  65.56
10 43.10  2.5 762.78  44.43
Fig. 5 Interaction of heparin with Arr3. (A) Summary of the number of
immobilized Arr3-WT molecules and bound heparin as a function of DGS-
NTA(Ni2+) content (B) summary of the bound heparin mass in the
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binding of JSR1 to Arr3 on the BLI sensor (association) followed
by a rinsing with buffer (dissociation) was monitored in real-time.
Binding association and dissociation rate constants (ka and kd,
respectively) for the JSR1 binding to the different Arr3 on BLI
biosensors were obtained by fitting the binding and dissociation
curves according to 1 : 1 binding model (Fig. 6).43 This model is
based on an equimolar interaction between ligand and analyte,44
assuming that JSR1 is homogenous, monomeric, does not aggre-
gate and only one molecule is bound per molecule of Arr3 on the
surface. This assumption was supported by stoichiometric
ratios between maximum binding response for JSR1 and
Arr3 r1 obtained with all platforms and thus, 1 : 1 binding
model was applied to all JSR1–Arr3 interactions. The equili-
brium dissociation constants (KD) for the JSR1 complexes with
different Arr3-BLI sensors were calculated from the fitted
kinetic constants as summarized in Table 3. The highest KD
was observed for the Arr3-X (389  59 nM) and the lowest KD for
the Arr3-Y (112  12 nM). Association and dissociation kinetic
constants show that JSR1 binds relatively fast to Arr3-WT and
its mutants. However, in the BLI setup, the half-life of the JSR1
Arr3 complexes is only around 3–4 s as was estimated from the
kinetic dissociation constants shown in Table 3. The kinetic
association constant for the JSR1-Arr3-Y complex was the fastest.
The exchange of positively charged arginine to negatively charged
glutamic acid in Arr3-Y might work as a switch in the polar core
that regulates the affinity of the adjacent finger loop of Arr3
towards JSR1. In contrast, the I386A mutation in Arr3-X may
make the interaction of the finger loop with JSR1 helices V and VI
less probable. Accordingly, the kinetic association constant was
the smallest.
For SPR measurements, all flow channels were first function-
alized with NTA(Ni2+)-SLM followed by Arr3 except for one
channel that was kept without Arr3 as a reference. The specificity
of the Arr3 binding to NTA(Ni2+)-SLM was validated by a return to
the SLM base line after the injection of 0.5 M EDTA or 0.5 M
imidazole that disrupts the histidine–Ni2+ interactions (not
shown). For more quantitative equilibrium and kinetic binding
analysis, a number of JSR1 concentrations (16.5, 31.25, 62.5, 125,
250, 500, 1000 nM) were injected into all flow channels followed
by 0.2 M NaOH to remove JSR1. After the reference subtraction,
the sensograms were fitted using 1 : 1 binding model to obtain
the kinetic constants (Fig. 7A). Additionally, the equilibrium
Fig. 6 Detection of DDM-stabilized JSR1 binding to Arr3-BLI sensors.
Representative JSR1 binding curves measured by BLI for (A) binding to
Arr3-WT (JSR1 concentrations: 0.2, 0.4, 0.8, 1.6, 3.2, 4.3 mM), (B) binding to
Arr3-X (JSR1 concentrations: 0.125, 0.25, 0.5, 1, and 4.3 mM), and (C) for
binding to Arr3-Y (JSR1 concentrations: 0.125, 0.250, 0.500, 1, and 4.3 mM)
immobilized on the Ni2+–NTA tips. Black curves are the experimental data
whereas red curves are the best fits.
Table 3 The equilibrium dissociation constants (KD) and kinetic association
(ka) and dissociation (kd) constants obtained for JSR1 (activated) complexes
with Arr3-WT, Arr3-X and Arr3-Y-BLI sensors Constants represent averages
 standard deviations of three independent measurements
Proteins KD, nM ka  105, M1 s1 kd, s1
Model for
kinetic fit
Arr3-WT 213  41 9.9  1.5 0.21  0.025 1 : 1 binding
Arr3-X 389  59 7.2  0.8 0.28  0.028 1 : 1 binding
Arr3-Y 112  12 11.3  0.9 0.13  0.009 1 : 1 binding
Fig. 7 Analysis of JSR1 binding to Arr3-SLM. (A) Representative kinetic fit
to 1 : 1 model for JSR1 binding to Arr3 immobilized on the Ni2+–NTA SLM
of HPA sensor chip. (B) Equilibrium binding analysis for the JSR1 binding to
Arr3-WT, Arr3-X and Arr3-Y. The solid lines represent a best fit to the
Langmuir binding isotherms. Black curves are the experimental data
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responses at different JSR1 concentrations were plotted and fitted
to the Langmuir binding isotherm (Fig. 7B). The obtained values
for the kinetic and equilibrium dissociation constants from SPR
measuremens show binding of JSR1 to all Arr3 (Tables 4 and 5,
respectively). However, the complexes dissociate slower than was
observed in the BLI measurements. It is possible that an inter-
action of Arr3 with the charged lipid head groups of the SLM on
the SPR sensor chip might induce slight conformational changes
that influence the dissociation and association kinetic rate of the
JSR1–Arr3 complex formation. Therefore, we have also fitted the
SPR data with the ‘two-state’ model that assumes a structural
re-arrangement after the fist binding step (see Fig. S4 and
Table S2, ESI†). However, the equilibrium binding constants
calculated from the kinetic constants using either model are
comparable with those obtained by BLI which could indicate
similar interactions but under different conformational conditions.
Since JSR1 was stabilized in DDM micelles, the measurements
at high JSR1 concentrations show some disruption of the lipid
monolayer due to the DDM exchange with SLM. Thus, the
equilibrium dissociation constants obtained from the equili-
brium fit (Fig. 7B) are less accurate than those calculated based
on the kinetic constants. Nevertheless, they are comparable to
those obtained using BLI within error limits.
The interaction of light-activated, DDM-stabilized JSR1 with
different Arr3 immobilized on SLBs was monitored by QCM-D.
Note that flowthrough experiments by QCM-D consume consider-
able amounts of protein because the measurement chamber is
bigger than in BLI and SPR. To conserve JSR1, we injected 1 mM
DDM-stabilized JSR1 to SLBs with/without Arr3 under continous
flow for only 2 min, stopped the flow, and then continued
the incubation for 30 min, after which stable frequency and
dissipation signals were observed. Unbound proteins were
removed by rinsing with buffer under continous flow. To first
evaluate the effect of the DDM micelles on SLBs with and
without Arr3, we performed QCM-D measurements with 0.01%
DDM micelles alone. Dm upon addition of DDM micelles was
55.57  29.22 ng cm2 (Fig. 8A), independent of the presence or
absence of Arr3 on SLBs. In contrast, injection of DDM-stabilized
JSR1 to Arr3-WT SLBs caused a increase in mass to 959.51 
384.97 ng cm2 (Fig. 8B). The Dm of 655.43  168.15 ng cm2 for
Arr3-X and Dm of 462.85  20.53 ng cm2 for Arr3-Y were in a
similar range. In the absence of Arr3 on the SLB platforms, the
Dm shift was considerably smaller (286.38  25.84 ng cm2). The
significant increase in mass indicates the specific interactions
between JSR1 and all three Arr3. The binding of JSR1 to Arr3 was
analyzed by fitting the data to a 1 : 1 binding model (Fig. S3, ESI†
and Table 6). The equilibrium dissociation constants were derived
from the kinetic constants obtained from the fits.
As expected, the obtained equilibrium dissociation constants
and the kinetic association and dissociation rates for Arr3–JSR1
complexes differ depending on the characterization method,
specifically on the different type of platforms. SPR and BLI
experiments led to small differences in the kinetic association
and dissosication rates indicating that on the SLM platform the
JSR1 association with Arr3 is faster and dissociation is slower
compared to complex formation on the SLB platform. This
finding results from the different properties of the membranes
on the sensor: SLM on the HPA chip is less fluidic than SLB on
the surface of the QCM-D sensor.45 It is well known that a water
Table 4 The equilibrium dissociation constants (KD) and kinetic association
(ka) and dissociation (kd) constants obtained for JSR1 (activated) complexes









Arr3-WT 170.3  55.7 0.33  0.27 4.55  0.02 1 : 1 binding
Arr3-X 152.6  27.5 2.97  0.06 10.97  0.50 1 : 1 binding
Arr3-Y 96.7  6.6 0.76  0.06 5.08  0.14 1 : 1 binding
Table 5 The equilibrium dissociation constants (KD) obtained for JSR1
(activated) complexes with Arr3 using SPR. Constants represent averages
standard deviations of three independent measurements
Proteins KD,
a nM Type of analysis
Arr3-WT 347.7  120.7 Equilibrium fit
Arr3-X 528  468 Equilibrium fit
Arr3-Y 616.3  319.3 Equilibrium fit
Fig. 8 Interaction of DDM-stabilized JSR1 s with immobilized Arr3. After
SLB formation and Arr3 immobilization, the system was re-equilibrated
and the mass baseline set to 0. Changes in mass were recorded over time,
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layer is present between a lipid bilayer and silicon dioxide
substrate.46 On the contrary, HPA surfaces are composed of
long chain octadekanethiol molecules that are covalently bound
to gold, forming a flat, quasi-crystalline hydrophobic layer. Thus,
the lateral mobility of the SLM and bound Arr3 is restricted on
HPA surfaces.47 This may impact on the conformation of Arr3
and its interactions with JSR1. In particular, the kinetic associa-
tion constants are much lower which might be due to a delay in
the recognition of the binding site that is linked to a certain
mobility of arrestin. The equilibrium dissociation constant
values obtained from QCM-D are higher compared to those of
the other two methods. Hence, the observed differences in binding
kinetics likely arise from intrinsic differences between the mono-
and bilayer membrane. In addition, the increase in the equilibrium
dissociation constant values obtained from QCM-D might be due to
differences in the extent of coupled water molecules that contribute
to the mass of proteins adsorbed on the sensors.
The kinetic association and dissociation constants derived
from BLI measurements suggest a faster complex formation than
observed with SPR and QCM-D, but equilibrium dissociation
constants are comparable with SPR values. It is also possible that
the fast binding kinetics arise from a lower protein density on the
tip surface, which improves the accessibility of the binding sites
compared to Arr3 on SLM or SLB platforms. Also, the tip surface
in this case might influence the binding less because DDM
micelles do not interact with BLI polymer coating. The binding
kinetics could also be influenced by the size of the flow cell and
the flow rate of the sample, both of which are different in all three
methods. Overall, the differences observed in the JSR1–Arr3
interaction indicate that the complex formation is influenced
by local conditions, such as the intrinsic property of the
membrane that hosts the Arr3. While all three methods are
suitable for measuring changes in the binding affinities between
GPCRs and arrestins, and can be used to quantitatively assess
changes in the complex stability caused by specific drugs, it is
important to take into account such local parameters when
comparisons between biosensing platforms are made. Therefore,
a combination of methods is necessary to ascertain how changes
to the environment impact on the interactions of GPCRs and
their associated proteins.
4 Conclusions
To overcome the challenges associated with the isolation,
reconstitution and oriented immobilization of GPCRs on
biosensors, we immobilized distinct variants of arrestin-3 by means
of histidine–NTA(Ni2+) interactions on different types of biosensors.
Using a combination of surface-based platforms, we demonstrate for
the first time that biophysical characterization of the selective
recognition and binding of JSR1 and wild type arrestin-3 and two
mutants by BLI, SPR and QCM-D is feasible. The characterization of
the kinetic properties of JSR1–arrestin-3 complex formation in terms
of binding constant, association and dissociation rates revealed
specific differences in JSR1 interaction with the arrestin-3 variants.
Interestingly, while disturbing access to the polar core did result in
an increased affinity in our system, in line with what has been
observed in cellular systems, the mutation affecting the three-
element interaction did not. It would be interesting to assess
whether this is also true for other GPCRs. If yes, it could mean that
additional proteins interacting with arrestin may play a role in
regulating arrestin–receptor interactions in cells. JSR1 has also been
suggested to be an appropriate basis for engineering of novel
optogenetic tools allowing for an optical control of diverse GPCR
signaling pathways.22,26,48 Establishing a reliable assay allowing for a
robust biophysical characterization of JSR1 with its cellular binding
partners is a critical step towards realizing the optogenetic potential
of this receptor. Our system can be readily used, not only to assess
other GPCR–arrestin interactions, but it also provides the basis for
probing binding properties of GPCRs with other protein partners.
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Screening, 2004, 9, 322–333.
25 T. A. Key, C. M. Vines, B. M. Wagener, V. V. Gurevich,
L. A. Sklar and E. R. Prossnitz, Traffic, 2005, 6, 87–99.
26 N. Varma, E. Mutt, J. Mühle, V. Panneels, A. Terakita,
X. Deupi, P. Nogly, G. F. Schertler and E. Lesca, Proc. Natl.
Acad. Sci. U. S. A., 2019, 201902192.
27 D. Ehrenberg, N. Varma, X. Deupi, M. Koyanagi, A. Terakita,
G. F. Schertler, J. Heberle and E. Lesca, Biophys. J., 2019,
116, 1248–1258.
28 A. Bandyopadhyay, N. Van Eps, B. T. Eger, S. Rauscher,
R. S. Yedidi, T. Moroni, G. M. West, K. A. Robinson, P. R.
Griffin and J. Mitchell, J. Mol. Biol., 2018, 430, 4102–4118.
29 D. Mayer, F. F. Damberger, M. Samarasimhareddy,
M. Feldmueller, Z. Vuckovic, T. Flock, B. Bauer, E. Mutt,
F. Zosel and F. H. Allain, Nat. Commun., 2019, 10, 1261.
30 D. Sun, M. K. Ostermaier, F. M. Heydenreich, D. Mayer,
R. Jaussi, J. Standfuss and D. B. Veprintsev, PLoS One, 2013, 8.
31 R. S. Haider, F. Wilhelm, A. Rizk, E. Mutt, X. Deupi, C. Peterhans,
J. Mühle, P. Berger, G. F. Schertler and J. Standfuss, Sci. Rep.,
2019, 9, 439.
32 G. Sauerbrey, Z. Phys., 1959, 155, 206–222.
33 B. A. Handbook, Biacore AB, GE Healthcare Life Sciences,
Uppsala, 1997.
34 N.-J. Cho, C. W. Frank, B. Kasemo and F. Höök, Nat. Protoc.,
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